Robeco Institutional Asset Management B.V. Sells 2,017 Shares of DaVita Inc. (NYSE:DVA)

Robeco Institutional Asset Management B.V. lowered its holdings in shares of DaVita Inc. (NYSE:DVA) by 4.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 38,982 shares of the company’s stock after selling 2,017 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in DaVita were worth $6,390,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Janney Montgomery Scott LLC increased its holdings in shares of DaVita by 16.4% during the 3rd quarter. Janney Montgomery Scott LLC now owns 24,591 shares of the company’s stock worth $4,031,000 after acquiring an additional 3,468 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new position in shares of DaVita in the third quarter valued at $273,000. First Trust Direct Indexing L.P. raised its position in shares of DaVita by 2.9% in the third quarter. First Trust Direct Indexing L.P. now owns 3,051 shares of the company’s stock valued at $500,000 after purchasing an additional 86 shares during the period. Creekmur Asset Management LLC lifted its stake in shares of DaVita by 1.9% during the 3rd quarter. Creekmur Asset Management LLC now owns 8,852 shares of the company’s stock worth $1,451,000 after buying an additional 163 shares during the last quarter. Finally, abrdn plc boosted its holdings in shares of DaVita by 1.2% during the 3rd quarter. abrdn plc now owns 189,065 shares of the company’s stock worth $30,719,000 after buying an additional 2,180 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Activity

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the transaction, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at $138,284,666.75. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 173,482 shares of company stock worth $27,387,069. Insiders own 2.00% of the company’s stock.

DaVita Trading Up 2.2 %

Shares of DVA stock opened at $150.37 on Friday. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. DaVita Inc. has a fifty-two week low of $82.18 and a fifty-two week high of $168.50. The company has a market cap of $12.33 billion, a PE ratio of 16.22, a P/E/G ratio of 0.82 and a beta of 0.89. The stock’s fifty day moving average price is $157.17 and its two-hundred day moving average price is $146.59.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same quarter in the prior year, the company earned $2.85 earnings per share. DaVita’s revenue for the quarter was up 4.6% compared to the same quarter last year. Equities analysts predict that DaVita Inc. will post 9.73 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on DVA shares. Truist Financial boosted their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Barclays upped their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. TD Cowen boosted their target price on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Bank of America raised their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. Finally, UBS Group increased their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.